Overview
What it is.
CJC-1295 is a GHRH analog engineered for a longer half-life than sermorelin. It is frequently formulated alongside a growth-hormone-releasing peptide such as ipamorelin for research into complementary signaling along the same GH-axis pathway.
Research Areas
- Studied for its potential role in sustaining natural growth hormone pulses
- Studied for its potential role in recovery-pathway research
- Studied for its potential role in lean body-composition research
- Studied for its potential role in sleep-quality research
Batch & Testing
Proof, not promises.
COA ships with every order
Every batch we release is independently HPLC tested before it ever reaches a lab bench. Browse the full certificate library.
Research Deep-Dive
How it works.
Research Deep-Dive
How it works.
CJC-1295 is a modified GHRH analog engineered for a much longer half-life than sermorelin, achieved by linking the active peptide fragment to a drug affinity complex (DAC) that binds circulating albumin. It's most often compounded alongside a growth-hormone-releasing peptide such as ipamorelin.
Like sermorelin, CJC-1295 activates the pituitary's GHRH receptor to stimulate the body's own GH release. The DAC modification and resistance to enzymatic breakdown extend its activity from hours to days, producing a sustained rise in GH and IGF-1 rather than a single short pulse.
Use Cases Explored
- Studied for its potential role in sustaining natural growth hormone pulses over a longer window than shorter-acting GHRH analogs
- Studied for its potential role in training recovery
- Studied for its potential role in lean body composition alongside diet and exercise
- Studied for its potential role in sleep quality
The Evidence
Randomized, placebo-controlled human dosing trials (Teichman et al., 2006)
Two randomized, double-blind, placebo-controlled ascending-dose trials in healthy adults found single injections raised GH 2- to 10-fold for 6+ days and IGF-1 1.5- to 3-fold for 9-11 days, with a cumulative effect across repeat dosing — real controlled human data, though from a short-term healthy-volunteer population, not a therapeutic-outcome trial.
Phase II lipodystrophy/GHD trial discontinued after a subject death
A later clinical program studying CJC-1295 for lipodystrophy and growth hormone deficiency was halted after a trial subject died; the investigator attributed it to unrelated coronary artery disease, but the sponsor stopped development as a precaution. A separate planned trial in HIV-associated visceral adiposity was also discontinued during recruitment with no results reported.
No FDA-approved product or label exists
Despite the positive dosing-trial data, CJC-1295 never completed development into an approved drug — its evidence base stops at Phase I/II, and there is no FDA label defining an approved dose, indication, or long-term safety profile.
Specifications
The essentials.
Specifications
The essentials.
- Vial Capacity
- 3 ml glass vial
- Form
- Lyophilized powder
- Solubility
- Reconstitute with bacteriostatic water
- Storage
- Store in a cool, dry place. Refrigerate at 2–8°C after reconstitution
- Shelf Life
- 24 months lyophilized; 4–6 weeks refrigerated after reconstitution
Questions
CJC-1295 (no DAC) FAQ
Questions
CJC-1295 (no DAC) FAQ
Why is CJC-1295 often paired with another peptide in research protocols?+
It acts on the GHRH receptor while peptides like ipamorelin act on a separate growth-hormone-releasing pathway — researchers frequently study the two together for their complementary mechanism.
Growth Hormone
CJC-1295 (no DAC)
Modified GRF 1-29
A longer-acting GHRH analog frequently studied alongside selective secretagogues.
Size
COA-backed guarantee — independently test any vial; if it's under 99% purity, full refund + testing costs covered.
All products sold by One Tap Peptides are intended for laboratory research use only. Not for human consumption. Not intended for animal use. Not intended for diagnostic or therapeutic purposes.
Related
